Nectar Lifescience Ltd

Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.10.89 today, marking a significant decline amid a broader market downturn and persistent company-specific headwinds.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Nectar Lifescience Ltd has declined to a fresh 52-week low, closing near Rs 11.21, marking a significant downturn in its stock performance amid persistent financial difficulties and subdued market sentiment.

Nectar Lifescience Ltd witnessed a sharp decline on 9 Mar 2026, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical company’s shares plunged to a new 52-week low of ₹11.13, marking a maximum daily loss of 4.18%, significantly underperforming its sector and the broader market.

Nectar Lifescience Ltd’s shares touched a fresh 52-week low of Rs.11.21 today, marking a significant decline amid ongoing financial pressures and subdued market performance. The stock has now fallen for two consecutive sessions, registering a cumulative loss of 6.48% over this period, underperforming its sector by 0.5% on the day.

Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 2 Mar 2026, hitting its lower circuit price limit of ₹11.59. The stock faced intense selling pressure, resulting in a maximum daily loss of 5.0%, signalling panic selling and a significant imbalance between supply and demand.

Nectar Lifescience Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.11.69 today, marking a significant decline in its stock price amid ongoing financial difficulties and underperformance relative to the broader market and its sector peers.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Nectar Lifescience Ltd has touched a new 52-week low of Rs.12.01 today, marking a significant decline amid ongoing financial difficulties and subdued market performance. The stock’s fall contrasts with the broader market’s modest gains, highlighting sector-specific pressures and company-specific challenges.

Nectar Lifescience Ltd’s shares declined to a fresh 52-week low of Rs.12.35 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting persistent financial pressures and subdued operational metrics.

Nectar Lifescience Ltd’s stock touched a fresh 52-week low of Rs.12.45 today, marking a significant decline amid a sustained downward trend. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting ongoing financial strains and subdued market performance over the past year.

Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 20 Feb 2026, hitting its lower circuit price limit and recording a maximum daily loss of 3.96%. The stock closed at ₹12.62, near its new 52-week low of ₹12.49, reflecting a sharp underperformance relative to its sector and the broader market.

Nectar Lifescience Ltd has touched a fresh 52-week low of Rs.12.75 today, marking a significant decline amid persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing financial pressures and subdued performance metrics.

Nectar Lifescience Ltd’s shares touched a fresh 52-week low of Rs.12.92 today, marking a significant decline amid sustained downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing financial pressures and subdued performance metrics.

Nectar Lifescience Ltd’s shares have declined to a fresh 52-week low, closing just 0.61% above the lowest price of Rs 13.1. The stock’s recent performance reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector, with the company’s market valuation and financial metrics signalling persistent challenges.

Nectar Lifescience Ltd’s shares declined to a fresh 52-week low of Rs.13.1 today, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent pressures on the company’s financial performance and market valuation within the Pharmaceuticals & Biotechnology sector.